139 related articles for article (PubMed ID: 25120841)
1. Blasts-more than meets the eye: evaluation of post-induction day 21 bone marrow in CBFB rearranged acute leukemia.
Xu X; Duncavage EJ
Int J Clin Exp Pathol; 2014; 7(7):4498-502. PubMed ID: 25120841
[TBL] [Abstract][Full Text] [Related]
2. Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm.
Salem A; Loghavi S; Tang G; Huh YO; Jabbour EJ; Kantarjian H; Wang W; Hu S; Luthra R; Medeiros LJ; Khoury JD
Am J Hematol; 2017 Jun; 92(6):520-528. PubMed ID: 28253536
[TBL] [Abstract][Full Text] [Related]
3. Acute myeloid leukemia with t(16;16) (p13;q22) showing a new CBFB-MYH11 fusion transcript associated with an atypical leukemic blasts morphology.
Albano F; Anelli L; Zagaria A; Coccaro N; Tota G; Impera L; Minervini CF; Cellamare A; Delia M; Minervini A; Casieri P; Specchia G
Hum Pathol; 2014 Mar; 45(3):643-7. PubMed ID: 24342433
[TBL] [Abstract][Full Text] [Related]
4. De Novo Acute Myeloid Leukemia with Combined
Sethapati VR; Jabr R; Shune L; El Atrouni W; Gonzales PR; Cui W; Golem S
Case Rep Hematol; 2020; 2020():8822670. PubMed ID: 33489389
[TBL] [Abstract][Full Text] [Related]
5. Marrow Hypocellularity, But Not Residual Blast Count or Receipt of Reinduction Chemotherapy, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia Patients With Morphologic Residual Disease.
Ollila TA; Olszewski AJ; Butera JN; Quesenberry MI; Quesenberry PJ; Reagan JL
Clin Lymphoma Myeloma Leuk; 2018 Mar; 18(3):204-209. PubMed ID: 29433979
[TBL] [Abstract][Full Text] [Related]
6. Concurrent acute myeloid leukemia with inv(16)(p13.1q22) and chronic lymphocytic leukemia: molecular evidence of two separate diseases.
Lu CM; Murata-Collins JL; Wang E; Siddiqi I; Lawrence H
Am J Hematol; 2006 Dec; 81(12):963-8. PubMed ID: 16917916
[TBL] [Abstract][Full Text] [Related]
7. Rare CBFB-MYH11 fusion transcripts in AML with inv(16)/t(16;16) are associated with therapy-related AML M4eo, atypical cytomorphology, atypical immunophenotype, atypical additional chromosomal rearrangements and low white blood cell count: a study on 162 patients.
Schnittger S; Bacher U; Haferlach C; Kern W; Haferlach T
Leukemia; 2007 Apr; 21(4):725-31. PubMed ID: 17287858
[TBL] [Abstract][Full Text] [Related]
8. The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemia.
Ouyang J; Goswami M; Tang G; Peng J; Ravandi F; Daver N; Routbort M; Konoplev S; Lin P; Medeiros LJ; Jorgensen JL; Wang SA
Am J Hematol; 2015 Jun; 90(6):504-10. PubMed ID: 25732229
[TBL] [Abstract][Full Text] [Related]
9. Low platelet count reduces subsequent complete remission rate despite marrow with <5% blasts after AML induction therapy.
Chen X; Newell LF; Xie H; Walter RB; Pagel JM; Sandhu VK; Becker PS; Hendrie PC; Abkowitz JL; Appelbaum FR; Estey EH
Leukemia; 2015 Aug; 29(8):1779-80. PubMed ID: 25650090
[No Abstract] [Full Text] [Related]
10. Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double-induction chemotherapy: Analysis from a large, single institution experience.
Griffin PT; Komrokji RS; Sweet K; Al Ali NH; Padron E; Kubal TE; List AF; Lancet JE
Am J Hematol; 2017 Mar; 92(3):232-237. PubMed ID: 28006850
[TBL] [Abstract][Full Text] [Related]
11. Molecular Basis and Targeted Inhibition of CBFβ-SMMHC Acute Myeloid Leukemia.
Castilla LH; Bushweller JH
Adv Exp Med Biol; 2017; 962():229-244. PubMed ID: 28299661
[TBL] [Abstract][Full Text] [Related]
12. A method comparison study of flow cytometry and cytomorphology to determine the percentages of blasts in patients with acute leukemia after induction and consolidation chemotherapy.
Wongprajun S; Auewarakul CU
J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S157-64. PubMed ID: 20364570
[TBL] [Abstract][Full Text] [Related]
13. Detection of a novel CBFB-MYH11 fusion transcript in acute myeloid leukemia M1 with inv(16)(p13q22).
Kurata K; Yamamoto K; Okazaki Y; Noguchi Y; Matsui K; Matsumoto H; Inui Y; Yakushijin K; Ito M; Nakamachi Y; Matsuoka H; Saegusa J; Minami H
Cancer Genet; 2020 Feb; 241():72-76. PubMed ID: 31353165
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow morphology during induction phase of therapy for acute myeloid leukemia (AML).
Dick FR; Burns CP; Weiner GJ; Heckman KD
Hematol Pathol; 1995; 9(2):95-106. PubMed ID: 7559259
[TBL] [Abstract][Full Text] [Related]
15. CD34 immunohistochemistry in bone marrow biopsies for early response assessment in acute myeloid leukemia.
Jain S; Mahapatra M; Pati HP
Int J Lab Hematol; 2015 Dec; 37(6):746-51. PubMed ID: 26248894
[TBL] [Abstract][Full Text] [Related]
16. CBFB and MYH11 in inv(16)(p13q22) of acute myeloid leukemia displaying close spatial proximity in interphase nuclei of human hematopoietic stem cells.
Weckerle AB; Santra M; Ng MC; Koty PP; Wang YH
Genes Chromosomes Cancer; 2011 Sep; 50(9):746-55. PubMed ID: 21638519
[TBL] [Abstract][Full Text] [Related]
17. Therapy-related myeloid neoplasm in an 18-year-old boy with B-lymphoblastic leukemia.
Qing X; Panosyan E; Yue C; Ji P; Gotesman M; French S; Cai J
Exp Mol Pathol; 2017 Dec; 103(3):263-266. PubMed ID: 29155023
[TBL] [Abstract][Full Text] [Related]
18. Is the D14 bone marrow in acute myeloid leukemia still the gold standard?
Ofran Y
Curr Opin Hematol; 2016 Mar; 23(2):108-14. PubMed ID: 26717195
[TBL] [Abstract][Full Text] [Related]
19. Peripheral blasts on day 21 of induction chemotherapy in a patient with core binding factor acute myeloid leukemia: more than meets the eye.
Parikh SA; Kadia T; Jabbour E
Clin Lymphoma Myeloma Leuk; 2010 Aug; 10(4):301-2. PubMed ID: 20709669
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Peripheral Blast Clearance and Day 14 Bone Marrow Biopsy in Predicting Remission Status and Survival After 7+3 Induction in Acute Myeloid Leukemia.
Covut F; Gupta D; Pinto R; Dambrosio N; El Jurdi N; Meyerson H; Ueda M; Kolk M; Creger R; Metheny L; Cooper BW; Caimi PF; Malek E; Otegbeye F; Lazarus HM; De Lima M; Tomlinson BK
Clin Lymphoma Myeloma Leuk; 2019 Feb; 19(2):73-82. PubMed ID: 30528848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]